3 completed. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Lipomed: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Rituximab, 2-CdA - Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 2 | Completed | Arbeitsgemeinschaft medikamentoese Tumortherapie | 40 | 2008-05-01 | 2013-12-24 |
| Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients Deferiprone (L1), Desferrioxamine - Hemochromatosis | Phase 2 | Completed | Lipomed | 24 | 2005-03-01 | 2011-12-12 |
| Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients Deferiprone (L1), Desferrioxamine - Hemochromatosis | Phase 3 | Completed | Lipomed | 95 | 2002-01-01 | 2012-11-19 |
Hemochromatosis (2) · Iron Overload (2) · Thalassemia (2) · Lymphoma, B-Cell, Marginal Zone (1)
Deferiprone (2) · Deferoxamine (2) · Long Interspersed Nucleotide Elements (2) · Cladribine (1) · Rituximab (1)
Austria (1) · Egypt (1) · Switzerland (1) · Turkey (Türkiye) (1)
Amal M El-Beshlawy, Prof. Dr. (1) · Markus Raderer, Prof. Dr. (1) · Markus Schmugge Liner, MD (1) · Yesim Aydinok, Prof. Dr. (1)
PMID 18055982, PMID 18351337, PMID 22180427, PMID 2265118, PMID 9633879